Literature DB >> 17613170

Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer.

Menha Swellam1, Lobna R Ezz El Arab, Hussein A Bushnak.   

Abstract

The aggressive biological behavior of invasive and metastatic cancer is considered to be the most insidious and life-threatening aspect for breast cancer patients. It is mostly the result of changes in many molecular characteristics of tumor cells, including alterations in gene expression and the balance of proteolytic activity. The objective of this study was to determine the level of MMP-2, its natural inhibitor TIMP-2, their ratio and HER-2/neu as diagnostic and prognostic factors. Markers were analyzed in 240 tissue samples categorized into 96 benign breast disease and 144 breast cancer patients. Enzyme linked immunosorbent assay procedure was used to evaluate the level of MMP-2 and TIMP-2 in the cell lysate, HER-2/neu in the membrane fraction, and steroid hormone receptors (ER and PgR) in the cytosol fraction. Breast cancer patients were followed-up for three years. Receiver operating characteristic curves were used to determine the cutoff points for the investigated factors. Positive values for all investigated factors were significantly increased in breast cancer patients compared to benign ones. Mean levels for all investigated factors were significantly correlated with lymph node and hormone receptor status, while MMP-2 and TIMP-2 were correlated with tumor grade (P < 0.05). In Univariate analysis, positive MMP-2, MMP-2/TIMP-2, HER-2/neu overexpression, higher tumor grade, late clinical stages and positive lymph nodes status were significantly associated with relapse. By multivariate analysis, all aforementioned factors apart from tumor grade were independent variables. Thus, the investigated markers are constructive for biologic aggressiveness of breast cancer and MMP-2/TIMP-2 ratio might be a new significant marker in early diagnosis and estimate prognosis in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613170     DOI: 10.1080/15216540701395074

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  3 in total

1.  Plasma matrix metalloproteinase 2 levels and breast cancer risk.

Authors:  Sarah A Aroner; Bernard A Rosner; Rulla M Tamimi; Shelley S Tworoger; Nadja Baur; Thomas O Joos; Susan E Hankinson
Journal:  Cancer Epidemiol       Date:  2015-03-19       Impact factor: 2.984

Review 2.  Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy.

Authors:  Alex Y Strongin
Journal:  Biochim Biophys Acta       Date:  2009-05-04

3.  Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.

Authors:  Nor Eddine Sounni; Dmitri V Rozanov; Albert G Remacle; Vladislav S Golubkov; Agnes Noel; Alex Y Strongin
Journal:  Int J Cancer       Date:  2010-03-01       Impact factor: 7.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.